News & Updates
Showing Cardiology articles
Showing
Show Multimedia Only

Can rosuvastatin protect against chemo-induced cardiotoxicity in HER2+ breast cancer?
22 Jul 2024
byNatalia Reoutova
Use of rosuvastatin is associated with a significantly lower decline in left ventricular ejection fraction (LVEF) and lower serum levels of cardiotoxicity-associated biomarkers in newly diagnosed HER2-positive breast cancer patients treated with anthracycline-based chemotherapy followed by trastuzumab, according to the results of a prospective, randomized, controlled, parallel study.
22 Jul 2024







